Management of pelvic endometriosis with low-dose danazol

E. E. Moore, J. H. Harger, J. A. Rock, D. F. Archer

Research output: Contribution to journalArticlepeer-review


Thirty-eight women with pelvic endometriosis diagnosed by laparotomy or laparoscopy were enrolled in a double-blind study utilizing danazol. Danazol was administered for 6 months in four doses schedules: 600, 400, 200, and 100 mg/day. At the completion of 6 months of therapy, repeat laparoscopy was performed and 71% of the women were found to have improvement of pelvic endometriosis. Minimal and moderate pelvic endometriosis appeared to respond well to doses of danazol of less than 400 mg/day, whereas severe endometriosis appeared to be best treated with danazol doses of greater than 400 mg/day. Symptomatic relief of pain, dysmenorrhea, and dyspareunia occurred in 89% of the women. The over-all pregnancy rate in women attempting conception was 28% (8 of 28). Fifty-one per cent of the women had recurrence of symptoms within 1 year of discontinuation of danazol.

Original languageBritish English
Pages (from-to)50-54
Number of pages5
JournalFertility and Sterility
Issue numberSUPPL. 2
StatePublished - 1985


Dive into the research topics of 'Management of pelvic endometriosis with low-dose danazol'. Together they form a unique fingerprint.

Cite this